Biomarker Predicts Effectiveness of Brain Cancer Treatment: Study

A new biomarker that predicts whether glioblastoma will respond to chemotherapy has been discovered by scientists.

A new biomarker that predicts whether glioblastoma will respond to chemotherapy has been discovered by scientists. The findings are published in the July print issue of Oncotarget.

"Every patient diagnosed with glioblastoma is treated with a chemotherapy called temozolomide. About 15 percent of these patients derive long-lasting benefit," said Clark C. Chen, MD, PhD, vice-chairman of Academic Affairs, Division of Neurosurgery, UC San Diego School of Medicine and the study's principal investigator. "We need to identify which patients benefit from temozolomide and which another type of treatment. All therapies involve risk and the possibility of side-effects. Patients should not undergo therapies if there's no likelihood of benefit."

About Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.

To pinpoint which patients were most likely respond to temozolomide, the researchers studied microRNAs that control the expression of a protein called methyl-guanine-methyl-transferase or MGMT. This protein dampens the cancer-killing effect of temozolomide. Tumors with high levels of MGMT are associated with a poor response to temozolomide therapy.

The scientists systematically tested every microRNA in the human genome to identify those that suppressed MGMT expression, with the expectation that high-levels of these microRNAs in the tumor would predict improved therapeutic response to temozolomide.

"We showed that a signature of the MGMT-regulating microRNAs predicted temozolomide response in a cohort of glioblastoma patients. Validation of these results should lead to diagnostic tools to enable us to determine which patients will benefit most from temozolomide therapy," said Chen.

New Therapeutic Vaccine Against Brain Cancer Demonstrates Positive Results
Oligodendrogliomas and Astrocytomas are subtypes of a brain cancer called 'glioma'.

In the study, the scientists also discovered that injection of the MGMT-regulating microRNAs into glioblastoma cells increased tumor sensitivity to temozolomide treatment.

"These findings establish the foundation for microRNAs-based therapies to increase the efficacy of temozolomide in glioblastoma patients," said lead author, Valya Ramakrishnan, PhD, postdoctoral researcher, UC San Diego School of Medicine.

New Genes That Promote Brain Cancer Discovered
GFI1 and GFI1B two oncogenes that promote the development of medulloblastoma have been discovered by scientists. Medulloblastoma is the most common malignant brain tumor in children.

Source-Eurekalert

Risk of Brain Cancer and Longer Telomeres
Two common gene variants that lead to longer telomeres, the caps on chromosome ends thought to confer health by protecting cells from ageing, can increase the risk of developing gliomas.